Thursday, April 6, 2023

What are advantages of using contract manufacturer?

Zuzana Jorová

Marketing & Sales Manager

Contract manufacturing is a business model continues to gain popularity in recent years. Companies that specialize in contract manufacturing, also known as contract development and manufacturing organizations (CDMOs), are increasingly being sought after by pharmaceutical and biotech companies that are looking for efficient and cost-effective ways to bring their products to market.

Here are some of the advantages of using CDMOs for drug development and manufacturing:

  1. Access to specialized expertise

CDMOs have highly skilled staff with expertise in a wide range of areas, including chemistry, biology, formulation development, and manufacturing. This specialized knowledge and experience is invaluable in overcoming technical challenges and accelerating the drug development process.

  1. Cost savings

Outsourcing drug development and manufacturing to CDMOs is cost-effective, as it eliminates the need for companies to invest in expensive equipment, facilities, and staff.

  1. Flexibility

From early-stage development to commercial-scale manufacturing – this allows companies to choose the services that best meet their needs, and to scale up or down as required.

  1. Quality and compliance

CDMOs are subject to rigorous quality and regulatory standards, which help to ensure that products are manufactured to the highest standards of safety and efficacy.

In the field of cytotoxic oncology products, the use of a CDMO can be particularly beneficial. Cytotoxic oncology products are used in the treatment of cancer and are designed to kill cancer cells. However, they can also be harmful to healthy cells in the body. The manufacture of cytotoxic oncology products requires specialized facilities and equipment, as well as highly trained staff who can handle these substances safely.

As a specialized CDMO we bring our expertise to sterile processing and aseptic Fill & Finish of complex formulations. Our state-of-the-art manufacturing facilities and experienced staff ensure that products are manufactured to the highest standards of quality and safety.

Our state-of-the-art technology comprises two production commercial lines dedicated to the manufacture of oncology vial injectables. Biomolecules are processed using a single-use system technology connected to the isolator concept line.

In addition to fill and finish, we also offer end-to-end solutions, which include formulation development, process optimization, analytical method development, and stability testing. By providing a comprehensive range of services, we ensure that our customers are able to bring a product to the market more quickly.

In conclusion, the use of a CDMO for cytotoxic oncology products can be highly beneficial for pharmaceutical and biotech companies. By outsourcing the manufacturing process to a specialized provider, companies can focus on their core competencies. As the pharmaceutical industry continues to evolve, the role of CDMOs is likely to become even more important in enabling companies to bring new drugs and therapies to market efficiently.

18. 4. 2024 | Articles Events

Line 3 – DCAT Announcement Forum

We had the opportunity to present information regarding our upcoming line for syringes, scheduled for launch in 2025.
read text
7. 2. 2024 | Articles Events

Mark your calendar: Upcoming events we’re thrilled to attend

In the upcoming months, we've curated a lineup of exceptional events, and we're eagerly looking forward to connecting with you at each one!
read text
9. 1. 2024 | Articles News

2023 milestones

2023 marked a transformative chapter for our company. Check out the milestones we reached last year.
read text